Investor Overview Recent News Jan 12, 2020 Summary ToggleAgios Announces “Agios 2025” Strategic Vision and Highlights 2020 Milestones full article Dec 23, 2019 Summary ToggleAgios to Present at the 38th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020 full article Dec 16, 2019 Summary ToggleAgios Receives FDA Breakthrough Therapy Designation for TIBSOVO® (ivosidenib) for the Treatment of Adult Patients with Relapsed or Refractory Myelodysplastic Syndrome with an IDH1 Mutation full article Dec 9, 2019 Summary ToggleAgios Presents Updated Data for Mitapivat from Extension Phase of the DRIVE PK Study in Patients with Pyruvate Kinase Deficiency full article Dec 9, 2019 Summary ToggleAgios Presents Translational Data to Further Characterize the Role of TIBSOVO® (ivosidenib) Treatment in IDH1 Mutant Acute Myeloid Leukemia (AML) full article Dec 8, 2019 Summary ToggleAgios Establishes Proof-of-Concept for Mitapivat in Non-transfusion-dependent Thalassemia Based on Preliminary Phase 2 Results full article View All Events & Presentations Feb 25, 2020 at 10:30 AM EST Agios at Leerink 9th Annual Global Healthcare Conference full article Jan 13, 2020 at 8:00 AM PST J.P. Morgan Q&A Breakout Session full article Jan 13, 2020 at 7:30 AM PST Agios at J.P. Morgan Healthcare Conference Supporting Materials: Agios at 38th Annual J.P. Morgan Conference 5.3 MB full article View All Analyst Coverage Firm Analyst Oppenheimer & Co. Mark Breidenbach Ph.D. Piper Jaffray & Co Tyler Van Buren RBC Capital Markets Kennen MacKay Ph.D. Pagination First page First Previous page Previous Page 1 Current page 2 Stock Information Price: Change: Volume: (Common Stock) Data as of Jan 20, 2020 2:08 pm EST Copyright West LLC. Minimum 15 minutes delayed.
Jan 13, 2020 at 7:30 AM PST Agios at J.P. Morgan Healthcare Conference Supporting Materials: Agios at 38th Annual J.P. Morgan Conference 5.3 MB